SNY Sep 2024 45.000 call
| Previous close | 3.0000 |
| Open | 3.4000 |
| Bid | 3.1000 |
| Ask | 7.1000 |
| Strike | 45.00 |
| Expiry date | 2024-09-20 |
| Day's range | 3.0000 - 3.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 30 |
ZacksRegeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
GlobeNewswirePress Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the outcomes from HARMONIE, a p
Insider MonkeySanofi (NASDAQ:SNY) Q1 2024 Earnings Call Transcript
Sanofi (NASDAQ:SNY) Q1 2024 Earnings Call Transcript April 25, 2024 Sanofi reports earnings inline with expectations. Reported EPS is $0.96 EPS, expectations were $0.96. Sanofi isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Paul Hudson: Welcome to the Q1 2024 conference […]
